MDT perspectives on the limitations of standard of care immunotherapy for non-driver mutation metastatic NSCLC
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the challenges associated with standard-of-care immunotherapy for metastatic NSCLC without driver mutations, including treatment resistance and toxicity.
The multidisciplinary team:
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/
Create your
podcast in
minutes
It is Free